FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions relates to a compound of formula (I) and specific compounds indicated in the claims, their pharmacologically acceptable salts, pharmaceutical compositions, uses and methods for inhibiting and treating cognitive impairment and Alzheimer's disease. In formula (I), Ra, Rb, Rc, Rd and Re are independently selected from the group consisting of H and CF3; R1 is selected from the group consisting of hydrogen or -CH=C(CH3)2; and R2 and its substituents are selected from the group of substituents given in the claims.
EFFECT: obtained compounds can inhibit the beta-amyloid effect on the neuron.
17 cl, 1 tbl, 342 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ISOINDOLINE COMPOSITIONS AND METHODS OF TREATING NEURODEGENERATIVE DISEASE | 2015 |
|
RU2692258C2 |
| COGNITIVE ABILITY REDUCTION INHIBITORS | 2010 |
|
RU2595720C2 |
| METHOD FOR COUNTERACTING FORMATION OF NEUROTOXIC PROTEINS ADDL (VERSIONS), METHOD FOR MODULATING NEURONAL DYSFUNCTION OR NEUROTOXICITY BY MEANS OF NON-PEPTIDE COMPOUND AND BASED COMPOSITION (VERSIONS) | 2007 |
|
RU2448694C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| COMPOUNDS APPLICABLE FOR NEURODEGENERATIVE DISORDERS | 2006 |
|
RU2461562C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE | 2012 |
|
RU2618412C2 |
| NEURODEGENERATIVE DISORDERS | 2015 |
|
RU2707191C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
